About US
Contact us
-
Generic industry's initial effort to halt Maryland price law rebuffed by judgeTaking a tough stance against Maryland's new pricing regulations, the generic drug industry sought an injunction, hoping to stop the law in its tracks. But the industry's efforts for relief have com2017/9/14
-
Takeda is expanding its EU presence while AstraZeneca talks of pulling production from U.K.While other companies fret about the impact of Brexit, Japan's Takeda will make another investment in its production operations in the European Union. The company will invest up to €100 million in2017/9/14
-
Teva makes good on asset-sale vows with $1.1B contraceptive saleMonday was quite the day for Teva. In addition to naming new CEO Kåre Schultz, the company unveiled the first of the asset sales it’s promised to help pay down debt. Late in the day, the embatt2017/9/13
-
Allergan, author of the 'social contract,' stirs up hornet's nest with controversial IP dealSeeking to shield its blockbuster eye drug against a second round of patent attacks, Allergan has transferred key Restasis intellectual propertyto the Saint Regis Mohawk Tribe.With the unusual move, t2017/9/13
-
Teva finally nabs a CEO, and it's Lundbeck helmsman—and Novo ex—Kåre SchultzAfter seven long months of searching, Teva finally has its new CEO—and as the company hinted it would, it’s poached him from another drugmaker. Lundbeck head honchoKåre Schultz, a longtime Novo2017/9/12
-
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivalsMADRID, Spain—Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting. And it keeps piling it on. Over the w2017/9/12
-
Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37%MADRID, Spain—Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo, r2017/9/11
-
ESMO: Lilly pads case for third-to-market abemaciclib with more positive breast cancer dataMADRID, Spain—Eli Lilly is gearing up to challenge Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negativebreast cancer, and it rolled out more positive data for candidate abemaciclib ove2017/9/11
-
Champions Oncology to collaborate with ALCMI to develop new cohort of PDX modelsChampions Oncology has entered into a collaboration deal with the Addario Lung Cancer Medical Institute (ALCMI) to develop a new cohort of PDX models in patients with ROS1 gene rearrangement. These m2017/9/8
-
US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitisThe US Food and Drug Administration (FDA) has accepted for filing Pfizer’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult p2017/9/8